SG10202011946PA - Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage - Google Patents

Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Info

Publication number
SG10202011946PA
SG10202011946PA SG10202011946PA SG10202011946PA SG10202011946PA SG 10202011946P A SG10202011946P A SG 10202011946PA SG 10202011946P A SG10202011946P A SG 10202011946PA SG 10202011946P A SG10202011946P A SG 10202011946PA SG 10202011946P A SG10202011946P A SG 10202011946PA
Authority
SG
Singapore
Prior art keywords
tissue
preventing
disorders associated
treating diseases
peptide analogs
Prior art date
Application number
SG10202011946PA
Inventor
Anthony Cerami
Michael Brines
Original Assignee
Araim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araim Pharmaceuticals Inc filed Critical Araim Pharmaceuticals Inc
Publication of SG10202011946PA publication Critical patent/SG10202011946PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
SG10202011946PA 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage SG10202011946PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6201208P 2008-01-22 2008-01-22
US6202208P 2008-01-22 2008-01-22
US6204508P 2008-01-22 2008-01-22
US13391208P 2008-07-03 2008-07-03
US20389008P 2008-12-30 2008-12-30

Publications (1)

Publication Number Publication Date
SG10202011946PA true SG10202011946PA (en) 2020-12-30

Family

ID=40810017

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2013011762A SG188161A1 (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
SG10201604530SA SG10201604530SA (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
SG10202011946PA SG10202011946PA (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG2013011762A SG188161A1 (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
SG10201604530SA SG10201604530SA (en) 2008-01-22 2009-01-22 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Country Status (15)

Country Link
US (4) US8853358B2 (en)
EP (2) EP2245056B1 (en)
JP (5) JP5542064B2 (en)
KR (7) KR101768792B1 (en)
CN (4) CN102066413B (en)
AU (1) AU2009206748B2 (en)
CA (1) CA2712757A1 (en)
ES (1) ES2539124T3 (en)
HK (2) HK1143822A1 (en)
IL (1) IL207155A (en)
MX (3) MX356129B (en)
NZ (3) NZ587105A (en)
PL (1) PL2245056T4 (en)
SG (3) SG188161A1 (en)
WO (1) WO2009094172A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
KR20170027868A (en) 2005-08-05 2017-03-10 아라임 파마슈티칼즈, 인크. Tissue protective peptides and uses thereof
SG188161A1 (en) 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9439925B2 (en) 2010-04-06 2016-09-13 Synedgen, Inc. Methods and compositions for treating wounds utilizing chitosan compounds
US9999702B2 (en) * 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
WO2012069474A2 (en) 2010-11-24 2012-05-31 H. Lundbeck A/S A method for reducing potential virus burden in a sample by cyanate treatment
US20130288373A1 (en) * 2010-12-20 2013-10-31 Kenneth Verstraete Crystal structure of flt3 ligand-receptor complex
CN103608026B (en) * 2011-06-13 2016-08-24 伊利诺伊大学受托管理委员会 Peptide combinations and for treating injury of lung, asthma, anaphylaxis, angioedema, the penetrating syndrome of Systemic Vascular and the method for nasal obstruction
FR2978964B1 (en) * 2011-08-09 2015-02-20 Conservatoire Nat Arts ANTI-IL-6 VACCINE COMPOSITION
CA2856329A1 (en) * 2011-11-17 2013-05-23 Nencki Institute Of Experimental Biology Compositions and methods for treating glioma
US10022393B2 (en) * 2012-09-20 2018-07-17 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
WO2014121063A1 (en) * 2013-01-31 2014-08-07 The Trustees Of The University Of Pennsylvania Repair of peripheral nerve injury
WO2014144095A2 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Oklahoma Compositions comprising d-amino acid peptides and methods of production and use thereof for inhibiting autoantibodies
JP6479789B2 (en) * 2013-07-17 2019-03-13 アライム ファーマシューティカルズ，インコーポレーテッド Tissue protective peptides and peptide analogs to prevent and treat diseases and disorders associated with tissue damage
KR101510743B1 (en) 2013-07-23 2015-04-10 (주)케어젠 Peptides Having an Inhibitory Activity on Osteoclast Differentiation and Uses Thereof
NZ721500A (en) 2014-02-10 2022-11-25 Fred Hutchinson Cancer Center Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
CN108125965B (en) * 2014-04-25 2020-04-10 广州市赛普特医药科技股份有限公司 Application of 5 α -androstane-3 β,5,6 β -triol and analogues thereof in altitude diseases
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
US20180292390A1 (en) * 2015-04-23 2018-10-11 Rowan University Novel slice cultures and methods for diagnosing neuronal degeneration diseases
CN105233256A (en) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 Application of erythropoietin and erythropoietin derivatives to preparation of medicine for promoting apoptotic cell clearance during disease treatment
RU2613308C1 (en) * 2015-11-23 2017-03-15 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method for prediction of predisposition to postoperative bleeding in case of pancreas head cancer
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN109310741A (en) * 2016-04-29 2019-02-05 阿拉伊姆药品公司 For preventing and treating organization protection's peptide of disease relevant to tissue damage and obstacle
CN106075392B (en) * 2016-07-18 2020-07-07 滨州医学院 Application of erythropoietin derivative in hearing protection
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
JP7123932B2 (en) * 2016-09-02 2022-08-23 クリストファー ジェイ． ソアレス Use of CGRP Receptor Antagonists in Neuroprotection and Neurological Disorders
CN110234311B (en) * 2016-11-10 2022-08-12 Asc瑞珍尼特有限公司 Cosmetic preparation for topical application containing erythropoietin-derived molecules
CN110475786A (en) * 2017-02-27 2019-11-19 大邱庆北科学技术院 Erythropoietin(EPO) derived peptide passes through its purposes to the effect of prevention cellular damage
JP6450999B2 (en) * 2017-03-31 2019-01-16 国立大学法人群馬大学 Treatment of Raynaud's phenomenon with botulinum toxin type B
AU2018261021A1 (en) * 2017-05-05 2019-12-12 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN107021996B (en) * 2017-05-24 2020-02-14 中国海洋大学 Short peptide, application thereof and antibacterial composition obtained from short peptide
CA3073379A1 (en) * 2017-08-19 2019-02-28 Ohio State Innovation Foundation Novel peptide-based cancer imaging agents
US20200223894A1 (en) * 2017-09-19 2020-07-16 Auckland Uniservices Limited Peptides for the treatment of conditions associated with adiponectin dysfunction
CN107880109B (en) * 2017-11-01 2019-08-30 复旦大学附属中山医院 A kind of hematopoietin source peptide and its preparation method and application
US10975124B2 (en) 2018-02-23 2021-04-13 The Board Of Regents Of The University Of Oklahoma Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor
KR102167641B1 (en) 2018-08-27 2020-10-19 주식회사 사이루스 Composition for growth-promoting cell containing erythropoietin-derived peptide
EP3849605A4 (en) 2018-09-10 2022-06-15 Cold Spring Harbor Laboratory Methods for treating pancreatitis
KR20200080179A (en) * 2018-12-26 2020-07-06 아미코젠주식회사 Peptide for inhibition of acetylcholine receptor and use thereof
AU2020417997A1 (en) * 2019-11-04 2022-06-16 Faraday Pharmaceuticals, Inc. Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity
WO2021245677A1 (en) * 2020-06-05 2021-12-09 Digestix Bioscience Inc. Compositions and methods for treating dysplastic and early-stage neoplastic conditions
CN111863118B (en) * 2020-07-20 2023-09-05 湖南莱博赛医用机器人有限公司 TCT and DNA ploidy analysis method based on TCT flaking
CN112557347B (en) * 2020-11-12 2023-10-24 渤海大学 Preparation and detection method of chyle particle migration model in mucus layer
KR20240036634A (en) * 2021-07-23 2024-03-20 레터럴 아이피 피티와이 리미티드 Peptide compositions capable of binding to lanthionine synthase C-like protein (LANCL) and uses thereof
CN114606317B (en) * 2022-03-22 2022-12-02 中山大学附属第一医院 Flora marker for predicting lymph node metastasis of gastric cancer and application thereof
CN117106057A (en) * 2022-08-19 2023-11-24 南京汉欣医药科技有限公司 High-purity human adrenocorticotropic hormone or analogue thereof and large-scale preparation method thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (en) 1975-05-30 1978-03-15 Battelle Memorial Institute
NO812612L (en) 1980-08-06 1982-02-08 Ferring Pharma Ltd ENZYME inhibitor.
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
DE3924746A1 (en) 1989-07-26 1991-01-31 Behringwerke Ag ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
US6932968B1 (en) 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US6849602B1 (en) 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
US6271196B1 (en) 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
US5952293A (en) 1996-03-08 1999-09-14 Receptron Receptor derived peptides involved in inhibition of receptor internalization in response to ligand binding
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
JP2003520194A (en) 1999-04-13 2003-07-02 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド Modulation of excitable tissue function by peripherally administered erythropoietin
WO2001083548A1 (en) 2000-04-28 2001-11-08 Effector Cell Institute Novel derivative of cell chemotactic factor
AU7490401A (en) * 2000-05-26 2001-12-11 Ortho Mcneil Pharm Inc Neuroprotective peptides
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
AU2002217984A1 (en) 2000-11-30 2002-06-11 Henry M. Jackson Foundation Erythropoietin and erythropoietin receptor expression in human cancer
PA8536201A1 (en) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EP1575499A2 (en) 2002-06-28 2005-09-21 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
AU2003251770B9 (en) * 2002-07-01 2009-06-04 H. Lundbeck A/S Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
ZA200505423B (en) 2002-09-09 2008-08-27 Warren Pharmaceuticals Inc Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
JP2004305006A (en) 2003-04-01 2004-11-04 Japan Science & Technology Agency Artificially prepared lung surfactant
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
ES2323465T3 (en) 2003-05-12 2009-07-16 Affymax, Inc. NOVELTY PEPTIDES THAT JOIN THE Erythropoietin Receptor.
JP2007512001A (en) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション EPO mimetic peptides and fusion proteins
CN1882355A (en) 2003-09-09 2006-12-20 沃伦药品公司 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CN1897959A (en) 2003-09-29 2007-01-17 沃伦药品公司 Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20050090551A1 (en) 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
US7842661B2 (en) * 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
DK2992901T3 (en) * 2004-02-02 2020-01-27 Engeneic Molecular Delivery Pty Ltd COMPOSITIONS AND PROCEDURES FOR TARGETING IN VITRO AND IN VIVO MEDICINE DELIVERY TO MAMMAL CELLS THROUGH BACTERIALLY DERIVATED INTAKE MINICELLS
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
EA012980B1 (en) * 2004-03-16 2010-02-26 Темпл Юниверсити Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Substituted phenoxy- and phenylthio-derivatives for treating proliferative disorders
WO2005099773A1 (en) 2004-04-05 2005-10-27 University Of Vermont And State Agricultural College Use of erythropoietin for treatment of cancer
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
KR20170027868A (en) 2005-08-05 2017-03-10 아라임 파마슈티칼즈, 인크. Tissue protective peptides and uses thereof
US20100040623A1 (en) 2005-12-20 2010-02-18 Elisabeth Bock Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
EP2120869A2 (en) 2006-12-18 2009-11-25 Altus Pharmaceuticals Inc. Human growth hormone formulations
SG188161A1 (en) 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Also Published As

Publication number Publication date
SG188161A1 (en) 2013-03-28
KR101572286B1 (en) 2015-11-27
NZ601868A (en) 2014-05-30
WO2009094172A2 (en) 2009-07-30
ES2539124T3 (en) 2015-06-26
MX2019011592A (en) 2019-11-21
KR20190085187A (en) 2019-07-17
US20150239932A1 (en) 2015-08-27
KR20200075044A (en) 2020-06-25
KR20100117616A (en) 2010-11-03
AU2009206748B2 (en) 2014-03-20
JP2014169308A (en) 2014-09-18
EP2245056A2 (en) 2010-11-03
CN111346213A (en) 2020-06-30
JP2021073281A (en) 2021-05-13
IL207155A (en) 2015-07-30
KR101850908B1 (en) 2018-04-20
CN102066413B (en) 2015-01-21
PL2245056T4 (en) 2016-01-29
AU2009206748A1 (en) 2009-07-30
WO2009094172A3 (en) 2009-12-10
US20170232066A1 (en) 2017-08-17
EP2245056B1 (en) 2015-03-11
US8853358B2 (en) 2014-10-07
JP2011527560A (en) 2011-11-04
JP2019123715A (en) 2019-07-25
US20200360476A1 (en) 2020-11-19
US9580465B2 (en) 2017-02-28
HK1143822A1 (en) 2011-01-14
US20110263504A1 (en) 2011-10-27
CA2712757A1 (en) 2009-07-30
CN102066413A (en) 2011-05-18
JP2017002040A (en) 2017-01-05
HK1215713A1 (en) 2016-09-09
SG10201604530SA (en) 2016-07-28
KR101768792B1 (en) 2017-08-16
IL207155A0 (en) 2010-12-30
KR20180041269A (en) 2018-04-23
MX356129B (en) 2018-05-16
EP2933264A3 (en) 2015-12-09
PL2245056T3 (en) 2015-08-31
CN108743916A (en) 2018-11-06
KR20170049616A (en) 2017-05-10
NZ621196A (en) 2015-08-28
KR20150134442A (en) 2015-12-01
MX2010008050A (en) 2011-02-23
KR20180123731A (en) 2018-11-19
CN104689298A (en) 2015-06-10
EP2933264A2 (en) 2015-10-21
NZ587105A (en) 2012-09-28
JP6309815B2 (en) 2018-04-11
JP5542064B2 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
HK1215713A1 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
IL251916A0 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP2307038A4 (en) Therapeutic agents comprising elastin-like peptides
IL210810B (en) Peptides for the treatment of pain and/or inflammation
EP2371375A4 (en) Peptide for inhibiting skin aging
IL243697A0 (en) Recombinant human cc10 protein for treatment of influenza
PL2496596T3 (en) Therapeutic peptides
HK1223298A1 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2274411A4 (en) Xanthohumol compositions and methods for treating skin diseases or disorders
EP2649095A4 (en) Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
HK1137623A1 (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof mntf
GB0908868D0 (en) Depsipeptide and their therapeutic use
GB0905970D0 (en) Depsipeptides and their therapeutic use
ZA201003806B (en) Recombinant lumpy skin disease virus for preventing aids
EP2254901A4 (en) Therapeutic peptides
EP2773365A4 (en) Peptide analogs for treating diseases and disorders
EP2484692A4 (en) Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
GB0809329D0 (en) Depsipeptides and their therapeutic use
GB201008106D0 (en) Cell protective peptides for treating diseases and disorders associated with tissue damage
ZA201209021B (en) Therapeutic peptide composition and method
GB0921430D0 (en) Protein for therapeutic use
GB0809324D0 (en) Depsipeptides and their therapeutic use
GB0809326D0 (en) Depsipeptides and their therapeutic use
GB0809328D0 (en) Depsipeptides and their therapeutic use
GB0809330D0 (en) Depsipeptides and their therapeutic use